Biomarker Study of ATH434 in Participants With MSA

Status:
Not yet recruiting

Trial end date:
2024-11-15

Target enrollment:

Participant gender:

This study will assess the safety and efficacy of ATH434 in participants with a clinical diagnosis of Multiple System Atrophy

Phase 2

Alterity Therapeutics